

Resource Summary Report

Generated by [kravitz2](#) on Jul 31, 2026

CiteFuse

RRID:SCR_019321

Type: Tool

Proper Citation

CiteFuse (RRID:SCR_019321)

Resource Information

URL: <https://sydneybiox.github.io/CiteFuse/>

Proper Citation: CiteFuse (RRID:SCR_019321)

Description: Software R package consisting of suite of tools for doublet detection, modality integration, clustering, differential RNA and protein expression analysis, antibody-derived tag evaluation, ligand-receptor interaction analysis and interactive web-based visualization of CITE-seq data.

Synonyms: Cellular Indexing of Transcriptomes and Epitopes Fuse, Cellular indexing of transcriptomes and epitopes Fuse

Resource Type: data processing software, software application, data analysis software, software resource

Defining Citation: [PMID:32353146](#)

Keywords: Data pre processing, modality integration, clustering, differential RNA, ADT, expression analysis, ADT evaluation, ligand receptor interaction analysis, CITE-seq data, cellular indexing of transcriptomes and epitopes by sequencing, bio.tools

Availability: Free, Available for download, Freely available

Resource Name: CiteFuse

Resource ID: SCR_019321

Alternate IDs: biotools:citefuse

Alternate URLs: <https://bioconductor.org/packages/CiteFuse/>, <https://github.com/SydneyBioX/CiteFuse/>, <http://shiny.maths.usyd.edu.au/CiteFuse/>, <https://bio.tools/CiteFuse>

License: GPL-3

Record Creation Time: 20220129T080344+0000

Record Last Update: 20260731T043050+0000

Ratings and Alerts

No rating or validation information has been found for CiteFuse.

No alerts have been found for CiteFuse.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 2 mentions in open access literature.

Listed below are recent publications. The full list is available at [kravitz2](#) .

Chen M, et al. (2025) SMOPCA: spatially aware dimension reduction integrating multi-omics improves the efficiency of spatial domain detection. Genome biology, 26(1), 135.

Foltz JA, et al. (2021) Phase I Trial of N-803, an IL15 Receptor Agonist, with Rituximab in Patients with Indolent Non-Hodgkin Lymphoma. Clinical cancer research : an official journal of the American Association for Cancer Research, 27(12), 3339.